Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 4/20 | 0.56 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.54 |
| ▸ | VIPR1 | P32241 | 3/20 | 0.54 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.54 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.53 |
| ▸ | TFPI | P10646 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412270 | 0.86 | VIPR2 (0.66) | VIPR1VIPR2PTH1R | |
| SCHEMBL29350082 | 0.85 | OPRL1 (0.61) | OPRL1VIPR1VIPR2PTH1R | |
| SCHEMBL29401001 | 0.85 | PTH1R (0.68) | VIPR1PTH1R | |
| SCHEMBL30711673 | 0.85 | PTH1R (0.68) | VIPR1PTH1R | |
| SCHEMBL29983249 | 0.83 | NR3C1 (0.69) | IL23RNR3C1 | |
| Magainin 2 SCHEMBL29374652 | 0.83 | PTH1R (0.66) | VIPR1PTH1R | |
| SCHEMBL29889765 | 0.83 | VIPR1 (0.58) | NR3C1VIPR1VIPR2 | |
| SCHEMBL31332217 | 0.83 | PTH1R (0.66) | VIPR1PTH1R | |
| SCHEMBL29587816 | 0.83 | VIPR2 (0.63) | VIPR1VIPR2PTH1R | |
| SCHEMBL29767317 | 0.81 | PTH1R (0.56) | VIPR1PTH1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022040799-A1 | ANTIMICROBIAL COMPOSITION | GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) | 2022-03-03 | — | — | WO | claimed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260014091-A1 | COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2025128946-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025128952-A1 | MANGANESE DOPED METAL ORGANIC FRAMEWORKS AND METHODS OF MAKING AND USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250135007-A1 | COMPOSITIONS COMPRISING STEROL-AMINO-PHOSPHATE COMPOUNDS AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION | 2025-05-01 | — | — | US | disclosed |
| EP-4536139-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | The Methodist Hospital (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20250099392-A1 | COMPOSITIONS COMPRISING LIPID COMPOUNDS AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION | 2025-03-27 | — | — | US | disclosed |
| WO-2023107400-A1 | DIAMINO LIPID (DAL) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING AN IMMUNOTHERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023086365-A1 | COMPOSITIONS COMPRISING AMINO LIPID COMPOUNDS AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230119855-A1 | HYDROGEL DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL SYSTEM | 2023-04-20 | — | — | US | disclosed |
| WO-2023064527-A1 | HYDROGEL DEVICES AND METHODS OF MAKING AND USE THEREOF | THE METHODIST HOSPITAL SYSTEM (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-3317294-B1 | STABILIZED ANTI-MICROBIAL PEPTIDES | DANA FARBER CANCER INST INC (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230046062-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USING THEREOF | ZEOVATION, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2022159787-A1 | COMPOUNDS FOR THE TREATMENT OF A DISEASE OR DISORDER, METHODS FOR IDENTIFYING SAID COMPOUNDS | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-07-28 | — | — | WO | disclosed |
| US-11325955-B2 | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| WO-2022040799-A1 | ANTIMICROBIAL COMPOSITION | GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) | 2022-03-03 | — | — | WO | disclosed |
| US-11246312-B2 | Antimicrobial compositions and methods of using same | CROWPIERCE TECHNOLOGIES, LLC (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014091-A1 | COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF | ERBB3, ERBB2, EGFR | IL23R 243/4885OPRL1 1303/4885NR3C1 2885/4885 |
| US-20250135007-A1 | COMPOSITIONS COMPRISING STEROL-AMINO-PHOSPHATE COMPOUNDS AND METHODS OF MAKING AND USE THEREOF | NASP, CYP27A1, CYP11A1 | IL23R 3759/4885OPRL1 4368/4885NR3C1 1889/4885 |
| US-11325955-B2 | Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections | MME, CLPP, VIP | IL23R 1632/4885OPRL1 3375/4885NR3C1 4510/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | IL23R 2413/4885OPRL1 4863/4885NR3C1 4692/4885 |
| US-20250099392-A1 | COMPOSITIONS COMPRISING LIPID COMPOUNDS AND METHODS OF MAKING AND USE THEREOF | LIPA, LIPC, SGMS2 | IL23R 4496/4885OPRL1 3385/4885NR3C1 3251/4885 |
| US-20230046062-A1 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF USING THEREOF | PRF1, LCT, DSTN | IL23R 4394/4885OPRL1 4111/4885NR3C1 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.